- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07948408
A Phase III Study of WSD0922-FU Versus Chemotherapy In Patients With C797S+ Advanced Non-small Cell Lung Cancer (WAYWIN-301)
An Open-label, Randomized, Controlled, Multicenter Phase III Clinical Study Evaluating the Efficacy and Safety of WSD0922-FU Monotherapy Versus Platinum-based Doublet Chemotherapy in Participants With EGFR C797S Mutation-positive, Locally Advanced/Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Developed Resistance to Prior First-line Third-generation EGFR-TKI Therapy.
This is an Open-label, Randomized, Controlled, Multicenter Phase III Study Evaluating Efficacy and Safety of WSD0922-FU Monotherapy versus Platinum-based Doublet Chemotherapy for Participants with EGFR C797S Mutation-positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease have Developed Resistance to Prior First-line Third-generation EGFR-TKI Therapy
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
- Navn: Wei Zhong, PhD
- Telefonnummer: 1-951-547-4692
- E-mail: wei.zhong@wayshinebiopharm.com
Undersøgelse Kontakt Backup
- Navn: Lily Liu, MD
- Telefonnummer: +8613818880308
- E-mail: lily.liu@wayshinebiopharm.com
Studiesteder
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina, 200123
- Shanghai East Hospital
-
Kontakt:
- Fei Zhou, MD
- Telefonnummer: +86 21-38804518
- E-mail: fei.zhou@tongji.edu.cn
-
Ledende efterforsker:
- Caicun Zhou, MD
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Histologically or cytologically confirmed locally advanced or metastatic NSCLC
- Eligible for platinum-based doublet chemotherapy
- Prior first-line treatment with monotherapy of third-generation EGFR-TKIs (osimertinib, Firmonertinib, Almonertinib, etc.) or third-generation EGFR-TKIs combined with anti-angiogenic drugs or Lazertinib combined with Amivantamab, confirmed by imaging evidence of disease progression, and no other systemic antitumor therapy was administered after progression
- Tissue sample confirmed C797S positive by central lab using NGS
- At least one measurable target lesion per RECIST v1.1 criteria
- ECOG 0-1
- Adequate organ function and bone marrow function
- Women should take appropriate contraceptive measures and should not breastfeed. If they have fertility, they must undergo a negative pregnancy test before starting medication
- Male participants should agree to the use of contraceptive measures
Exclusion Criteria:
- Presence of clear bypass tumor driver (e.g., KRAS activating mutations, Braf V600E, MET exon 14 skipping, HER2 mutations, RET fusion, ROS1 fusion etc.)
- Histological or phenotypic transformation
- Any severe or uncontrolled systemic disease
- ≥ Grade 2 toxicities per CTCAE v6.0 attributed to prior anti-tumor therapy except hearing loss, hair loss, and fatigue
- Participants with leptomeningeal, brainstem, or spinal cord metastases and/or spinal cord compression, as well as active brain metastases, increased intracranial pressure or associated risks (such as intracranial hemorrhage or intracranial infection), or symptomatic cerebral complications requiring urgent neurosurgical or pharmacological (e.g., mannitol) intervention
- A history of interstitial lung disease (ILD), drug-induced ILD, or non-infectious pneumonitis requiring steroid treatment; or suspected ILD or non-infectious pneumonitis that can't be ruled out by imaging at the time of screening
- Clinically significant cardiac abnormalities or severe/uncontrolled/active cardiovascular disease
- Significant clinical bleeding tendency or history of severe arterial/venous thromboembolic events
- Poorly controlled diabetes mellitus or hypertension
- History of other primary malignancies within two years
- Known active or suspected autoimmune diseases; or known active ocular diseases (such as active wet age-related macular degeneration, diabetic retinopathy with macular edema)
- Active infectious diseases (e.g., active HIV, HBV and HCV)
- Known alcohol or drug dependence
- Mental disorders or poor compliance
- The investigator believes that the subject has other reasons that make them unsuitable for participating in this clinical study
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: WSD0922-FU Tablet
|
Participants will take WSD0922-FU 120 mg BID under fasted condition, administered orally; treatment cycles are 21 days in duration, continuing until disease progression, occurrence of intolerable toxicity, withdrawal of informed consent, death, or fulfillment of other protocol-specified criteria for treatment discontinuation
Andre navne:
|
|
Aktiv komparator: Platinum-Based Doublet Chemotherapy
|
Participants will receive 4 cycles of standard platinum-based doublet chemotherapy (selected by the investigator based on participant's condition and tolerance): Option 1: Pemetrexed 500 mg/m² IV infusion + Cisplatin 75 mg/m² IV infusion on Day 1 of each 21-day cycle. Option 2: Pemetrexed 500 mg/m² IV infusion + Carboplatin AUC 5 IV infusion on Day 1 of each 21-day cycle. Followed by maintenace of Pemetrexed 500 mg/m² IV infusion until disease progression, occurrence of intolerable toxicity, withdrawal of informed consent, death, or fulfillment of other protocol-specified criteria for treatment discontinuation
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression Free Survival (PFS)
Tidsramme: From date of randomization until the date of BICR confirmed progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
PFS as assessed by Blinded independent Central Review (BICR) per RECIST 1.1 |
From date of randomization until the date of BICR confirmed progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall Survival (OS)
Tidsramme: From the date of randomization to the date of death from any cause, assessed up to 36 months.
|
OS |
From the date of randomization to the date of death from any cause, assessed up to 36 months.
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
PFS as assessed by investigator per RECIST 1.1
Tidsramme: From date of randomization until the date of investigator confirmed progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
From date of randomization until the date of investigator confirmed progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
|
Objective Response Rate (ORR)
Tidsramme: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
ORR as assessed by investigator and BICR per RECIST 1.1 |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
Duration of Response (DOR)
Tidsramme: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
DoR by BICR and Investigator per RECIST 1.1 |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
Disease Control Rate (DCR)
Tidsramme: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
DCR by BICR and Investigator per RECIST 1.1 |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
Time to Disease Progression (TTP)
Tidsramme: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
TTP by BICR and Investigator per RECIST 1.1 |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
Time to Response (TTR)
Tidsramme: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
TTR by BICR and Investigator per RECIST 1.1 |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
Intracranial ORR (icORR)
Tidsramme: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
icORR by BICR and Investigator per RANO-BM |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
Intracranial PFS (icPFS)
Tidsramme: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
icPFS by BICR and Investigator per RANO-BM |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
Intracranial DOR (icDOR)
Tidsramme: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
icDOR by BICR and Investigator per RANO-BM |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
Intracranial DCR (icDCR)
Tidsramme: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
icDCR by BICR and Investigator per RANO-BM |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
Intracranial TTP (icTTP)
Tidsramme: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
icTTP by BICR and Investigator per RANO-BM |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
Intracranial TTR (icTTR)
Tidsramme: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
icTTR by BICR and Investigator per RANO-BM |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
AE and SAE
Tidsramme: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
AE and SAE per CTCAE 6.0 |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire, Core 30
Tidsramme: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
Quality of life according to the EORTC QLQ-C30 test results from a minimum of 0 to a maximum of 100, where higher scores represent either a better or worse outcome depending on the specific subscale |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
|
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer 13
Tidsramme: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
Quality of life according to the EORTC QLQ-LC13 test results from a minimum of 0 to a maximum of 100, where higher scores indicate a worse outcome |
From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Caicun Zhou, MD, Shanghai East Hospital
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Hjernesygdomme
- Sygdomme i centralnervesystemet
- Sygdomme i nervesystemet
- Neoplasmer efter sted
- Neoplasmer
- Luftvejssygdomme
- Lungesygdomme
- Neoplasmer i luftvejene
- Thoracale neoplasmer
- Lungeneoplasmer
- Neoplasmer i nervesystemet
- Karcinom, bronkogent
- Bronkiale neoplasmer
- Neoplasmer i centralnervesystemet
- Karcinom, ikke-småcellet lunge
- Neoplasmer i hjernen
- Aminosyrer, peptider og proteiner
- Organiske kemikalier
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ring
- Uorganiske kemikalier
- Klorforbindelser
- Nitrogenforbindelser
- Koordinationskomplekser
- Guanine
- Hypoxanthines
- Purinoner
- Puriner
- Glutamater
- Aminosyrer, sur
- Aminosyrer
- Aminosyrer, dicarboxylic
- Platinforbindelser
- Pemetrexed
- Carboplatin
- Cisplatin
Andre undersøgelses-id-numre
- WSD0922-301
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .